Business Description
Supernus Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US8684591089
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.14 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.46 | |||||
Interest Coverage | 5.55 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.97 | |||||
Beneish M-Score | -2.76 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.1 | |||||
3-Year EBITDA Growth Rate | -25.5 | |||||
3-Year EPS without NRI Growth Rate | -50.7 | |||||
3-Year FCF Growth Rate | -7.4 | |||||
3-Year Book Growth Rate | 6.1 | |||||
Future 3-5Y Total Revenue Growth Rate | 4.5 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 54.88 | |||||
9-Day RSI | 44.17 | |||||
14-Day RSI | 44.37 | |||||
6-1 Month Momentum % | 43.83 | |||||
12-1 Month Momentum % | -8.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.7 | |||||
Quick Ratio | 1.43 | |||||
Cash Ratio | 0.88 | |||||
Days Inventory | 378.28 | |||||
Days Sales Outstanding | 87.9 | |||||
Days Payable | 27.74 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | 16.81 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 86.21 | |||||
Operating Margin % | 2.21 | |||||
Net Margin % | 0.22 | |||||
FCF Margin % | 18.19 | |||||
ROE % | 0.14 | |||||
ROA % | 0.09 | |||||
ROIC % | 0.57 | |||||
ROC (Joel Greenblatt) % | 5.08 | |||||
ROCE % | 0.51 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio without NRI | 113.76 | |||||
Shiller PE Ratio | 22.41 | |||||
Price-to-Owner-Earnings | 33.38 | |||||
PS Ratio | 2.79 | |||||
PB Ratio | 1.8 | |||||
Price-to-Tangible-Book | 8.09 | |||||
Price-to-Free-Cash-Flow | 15.74 | |||||
Price-to-Operating-Cash-Flow | 15.66 | |||||
EV-to-EBIT | 275.39 | |||||
EV-to-EBITDA | 15.85 | |||||
EV-to-Revenue | 2.35 | |||||
EV-to-FCF | 12.92 | |||||
Price-to-Projected-FCF | 0.86 | |||||
Price-to-Median-PS-Value | 0.61 | |||||
Price-to-Graham-Number | 6.4 | |||||
Price-to-Net-Current-Asset-Value | 12.1 | |||||
Earnings Yield (Greenblatt) % | 0.36 | |||||
FCF Yield % | 6.67 | |||||
Forward Rate of Return (Yacktman) % | -4.33 |